Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed JIA
NCT05310799 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 842
Last updated 2023-12-06
Summary
The PERSON-JIA Trial is a cluster-randomized trial testing the use of Shared Decision Making (SDM) with families for treatment of children with arthritis. The intervention is a discussion between physicians and families at the time of diagnosis that uses computer-generated personalized outcome reports generated by previously developed prediction algorithms.
By using information provided by thousands of families, the investigators have developed a way of providing answers to common questions asked by patients and their families at diagnosis.
We will test whether a structured discussion and shared decision between families and doctors (guided by the patient's personal report) will improve the tailoring of treatment to the child and control of their disease. The personal report is called the PERSON-JIA report and presents the child's expected disease severity, the likelihood the child will be arthritis free by age 18 and the chance treatments will be effective and/or have side effects. This way, answers to these questions can be shared by physicians and families to weigh potential benefits and harms according to family values and preferences.
The investigators expect that using the personalized report in a frank and thoughtful discussion will help physicians and families make better decisions about managing the child's disease. This in turn will result in better disease control, greater family engagement and satisfaction with care and better-tailored treatment. If so, this will be a ground-breaking way of using information provided by families and doctors to improve the care provided to and the outcomes of children with arthritis in Canada.
Conditions
- Juvenile Idiopathic Arthritis
Interventions
- OTHER
-
Shared Decision Making (SDM)
The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
Sponsors & Collaborators
-
Canadian Institutes of Health Research (CIHR)
collaborator OTHER_GOV -
The Arthritis Society, Canada
collaborator OTHER -
University of British Columbia
lead OTHER
Principal Investigators
-
Lori B Tucker, MD · University of British Columbia Department of Pediatrics
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-23
- Primary Completion
- 2028-02-29
- Completion
- 2029-02-28
Countries
- Canada
Study Locations
More Related Trials
-
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
NCT00339157 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
NCT00570661 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
NCT00048542 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
NCT00690573 ·Status: COMPLETED ·Phase: PHASE3
-
Start Time Optimization of Biologics in Polyarticular JIA
NCT02593006 ·Status: COMPLETED
-
Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
NCT01557452 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT01844518 ·Status: COMPLETED ·Phase: PHASE3
-
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
NCT03510442 ·Status: RECRUITING
-
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
NCT03841357 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis
NCT01261624 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT01455701 ·Status: COMPLETED ·Phase: PHASE1
-
The Treat-to-target Study of RA Based on Smart System of Disease Management(SSDM)
NCT03715595 ·Status: UNKNOWN ·Phase: NA
-
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
NCT01835470 ·Status: COMPLETED ·Phase: PHASE3
-
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
NCT00095173 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT05411211 ·Status: COMPLETED
-
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
NCT01235598 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
NCT01673919 ·Status: COMPLETED ·Phase: PHASE3
-
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
NCT01015547 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773978 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis
NCT02919761 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
NCT02277444 ·Status: COMPLETED ·Phase: PHASE3
-
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
NCT05754710 ·Status: RECRUITING